Drugs / Vobarilizumab
last change Aug 2018 re-read 2 minutes ago

Vobarilizumab

also known as ALX-0061

Protein / enzyme biologic targets IL6R

Developed for
rheumatoid arthritis · systemic lupus erythematosus
Investigated by
Ablynx, a Sanofi company

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02101073 Mar → Jul 2014 rheumatoid arthritis Ablynx, a Sanofi company Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT01284569 Mar 2011 → Sep 2012 rheumatoid arthritis Ablynx, a Sanofi company Completed No outcome recorded
Phase 24 trials
Phase 2 NCT02437890 Jul 2015 → Jan 2018 systemic lupus erythematosus Ablynx, a Sanofi company Completed No outcome recorded
Phase 2 NCT02518620 Jul 2015 → Aug 2018 rheumatoid arthritis Ablynx, a Sanofi company Completed No outcome recorded
Phase 2 NCT02287922 Mar 2015 → Jul 2016 rheumatoid arthritis Ablynx, a Sanofi company Completed No outcome recorded
Phase 2 NCT02309359 Jan 2015 → Aug 2016 rheumatoid arthritis Ablynx, a Sanofi company Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2013-09-23 AbbVie Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases abbvie.com

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Vobarilizumab Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes.” NCT02437890
Known as ALX-0061 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01284569
5

NCT02287922

NCT02101073

NCT02437890

NCT02309359

NCT02518620

Modality Protein / enzyme biologic “ALX-0061, a Nanobody targeting the receptor for interleukin 6 (IL6R)” NCT01284569
Route Intravenous Intravenous administration” NCT01284569
Target IL6R “Nanobody targeting the receptor for interleukin 6 (IL6R)” NCT01284569